Study of NXP900 With Lorlatinib in ALK+ Lung Cancer

This is a multi-center, open label, Phase 1b study of NXP900 in combination with lorlatinib in subjects with advanced, ALK-positive non-small cell lung cancer (NSCLC)

Trial Details

NCT ID
NCT07784959
Phase
PHASE1
Sponsor
Nuvectis Pharma, Inc.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • NXP900
  • Lorlatinib
Locations (sample)
  • Fairfax, Virginia, United States|38.84622,-77.30637

Key Eligibility Criteria

  • 18 years old or older
  • Unresectable, metastatic or locally advanced ALK-positive NSCLC.
  • Must have received lorlatinib as first or second line TKI
  • One prior line of systemic chemotherapy is permitted

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →